IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for

Vinay Tergaonkar1, Virginie Bottero, Masahito Ikawa

  • 1Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.

Insights

This study reveals a new way chemotherapy drug doxorubicin activates NF-kappaB in cancer cells lacking IKK1/2. Blocking proteasome activity enhances chemotherapy effectiveness by inhibiting this NF-kappaB activation pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Nuclear factor kappa B (NF-kappaB) promotes tumor survival and chemotherapy resistance.
  • NF-kappaB activation involves the degradation of its inhibitor, IkappaB.
  • IKappaB kinases (IKK1 and IKK2) are traditionally linked to IkappaB degradation.

Purpose of the Study:

  • To investigate a novel IkappaB degradation mechanism independent of IKK1/2.
  • To explore the role of this pathway in chemotherapy resistance.
  • To identify potential therapeutic targets for enhancing anticancer treatments.

Main Methods:

  • Utilized IKK1/2-deficient mouse embryo fibroblasts (MEFs).
  • Administered doxorubicin (DoxR) to induce IkappaB degradation.
  • Assessed IkappaBalpha degradation, NF-kappaB reporter gene activity, and endogenous gene expression.
  • Investigated the role of phosphatidylinositol 3-kinase (PI3K) and proteasome inhibition.

Main Results:

  • Doxorubicin induced IkappaBalpha degradation in IKK1/2(-/-) MEFs via a non-classical pathway, independent of serine 32/36 phosphorylation and the PEST domain.
  • This degradation was partially blocked by the PI3K inhibitor LY294002 and mediated by the proteasome.
  • Activated NF-kappaB in these cells could still induce target gene expression.
  • Combined doxorubicin treatment and proteasome inhibition significantly enhanced cell death in IKK1/2(-/-) MEFs.

Conclusions:

  • A novel, IKK1/2-independent pathway for NF-kappaB activation exists, triggered by DNA damage.
  • NF-kappaB modification by IKK1/2 is not essential for gene expression following DNA damage.
  • Proteasome inhibitors can serve as effective adjuvants in chemotherapy by targeting this alternative NF-kappaB activation route.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...